Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADTX Aditxt	$1.20 +3.0%	$1.45	$1.05 ▼ $21,400.00	$2.53M	1.49	962,278 shs	74,732 shs
GLYC GlycoMimetics	$0.16 -6.6%	$13.48	$14.06 ▼ $63.00	$10.00M	1.62	67,201 shs	1.05 million shs
GNPX GENPREX	$0.25 -9.4%	$0.28	$0.20 ▼ $3.97	$8.32M	-0.5	4.20 million shs	749,992 shs
LSB LakeShore Biopharma	$1.09 +4.3%	$1.05	$0.87 ▼ $8.60	$9.68M	0.58	137,863 shs	17,125 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADTX Aditxt	0.00%	-3.33%	-12.78%	-47.98%	-99.99%
GLYC GlycoMimetics	0.00%	0.00%	0.00%	-99.30%	-99.45%
GNPX GENPREX	0.00%	0.00%	+4.93%	+23.01%	-85.73%
LSB LakeShore Biopharma	0.00%	-3.69%	+6.13%	-18.74%	-78.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADTX Aditxt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GLYC GlycoMimetics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GNPX GENPREX	0.739 of 5 stars	0.0	2.0	0.0	4.7	0.6	0.0	0.6
LSB LakeShore Biopharma	0.3526 of 5 stars	0.0	3.0	0.0	0.0	0.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADTX Aditxt	0.00	N/A	N/A	N/A
GLYC GlycoMimetics	2.50	Moderate Buy	N/A	N/A
GNPX GENPREX	0.00	N/A	N/A	N/A
LSB LakeShore Biopharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADTX Aditxt	$130K	19.49	N/A	N/A	($1.52) per share	-0.79
GLYC GlycoMimetics	$10K	1,000.25	N/A	N/A	$0.08 per share	1.94
GNPX GENPREX	N/A	N/A	N/A	N/A	$0.15 per share	N/A
LSB LakeShore Biopharma	$80.82M	N/A	N/A	N/A	$8.86 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADTX Aditxt	-$34.45M	N/A	0.00	∞	N/A	-46,082.47%	-389.10%	-84.71%	8/18/2025 (Estimated)
GLYC GlycoMimetics	-$37.88M	-$0.46	N/A	N/A	N/A	N/A	-230.74%	-177.39%	8/6/2025 (Estimated)
GNPX GENPREX	-$21.11M	N/A	0.00	N/A	N/A	N/A	-664.65%	-370.18%	8/8/2025 (Estimated)
LSB LakeShore Biopharma	-$61.09M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/21/2025 (Estimated)

Latest ADTX, LSB, GLYC, and GNPX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	N/A	GNPX GENPREX	-$0.71	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	ADTX Aditxt	-$26,400.00	-$8.12	+$26,391.88	-$8.12	$0.43 million	$0.00 million
5/14/2025	Q1 2025	GLYC GlycoMimetics	-$5.00	-$4.00	+$1.00	-$0.04	N/A	N/A
5/12/2025	Q1 2025	GNPX GENPREX	-$0.82	-$0.26	+$0.56	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADTX Aditxt	N/A	N/A	N/A	N/A	N/A
GLYC GlycoMimetics	N/A	N/A	N/A	N/A	N/A
GNPX GENPREX	N/A	N/A	N/A	N/A	N/A
LSB LakeShore Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADTX Aditxt	N/A	0.08	0.08
GLYC GlycoMimetics	N/A	1.92	1.92
GNPX GENPREX	N/A	1.94	1.94
LSB LakeShore Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADTX Aditxt	15.54%
GLYC GlycoMimetics	75.19%
GNPX GENPREX	14.05%
LSB LakeShore Biopharma	52.64%

Insider Ownership

Company	Insider Ownership
ADTX Aditxt	0.01%
GLYC GlycoMimetics	8.70%
GNPX GENPREX	0.44%
LSB LakeShore Biopharma	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADTX Aditxt	60	2.12 million	2.12 million	No Data
GLYC GlycoMimetics	50	64.53 million	58.90 million	Optionable
GNPX GENPREX	20	33.15 million	33.00 million	No Data
LSB LakeShore Biopharma	773	N/A	N/A	N/A

ADTX, LSB, GLYC, and GNPX Headlines

Recent News About These Companies

LakeShore Biopharma secures $15 million in private placement

July 10, 2025 | uk.investing.com

LakeShore Biopharma Announces US$15 Million Private Placement Financing

July 8, 2025 | prnewswire.com

LakeShore Biopharma Co., Ltd (LSB) - Yahoo Finance

July 2, 2025 | finance.yahoo.com

LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell)

April 23, 2025 | prnewswire.com

LSB Industries, Inc. Schedules 2024 Fourth Quarter and Full Year Financial Results Release for Wednesday, February 26th and Conference Call for Thursday, February 27th

February 6, 2025 | businesswire.com

LakeShore Biopharma’s Financial Leap and Rabies Vaccine Trial Approval

December 19, 2024 | markets.businessinsider.com

LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance

December 19, 2024 | prnewswire.com

LakeShore Biopharma Co., Ltd: LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China

December 13, 2024 | finanznachrichten.de

LakeShore Biopharma Faces Challenges Amid Criminal Probe into Former Chairman

December 12, 2024 | markets.businessinsider.com

LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China

December 12, 2024 | globenewswire.com

LakeShore Biopharma Co Ltd Ordinary Shares

November 23, 2024 | morningstar.comM

LakeShore Biopharma Advances PIKA Rabies Vaccine Approval

November 8, 2024 | markets.businessinsider.com

LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of Pakistan

November 7, 2024 | markets.businessinsider.com

LakeShore Biopharma Announces Leadership Transition

November 2, 2024 | markets.businessinsider.com

LakeShore Biopharma Achieves Nasdaq Compliance Milestone

October 29, 2024 | markets.businessinsider.com

LakeShore Biopharma regains ompliance with Nasdaq minimum bid price requirement

October 29, 2024 | markets.businessinsider.com

LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

October 29, 2024 | prnewswire.com

LakeShore Biopharma Advances with Rabies Vaccine Trial

October 25, 2024 | markets.businessinsider.com

LakeShore’s YSJA rabies vaccine receives approval for Phase III trial in China

October 25, 2024 | markets.businessinsider.com

LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine

October 25, 2024 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADTX, LSB, GLYC, and GNPX Company Descriptions

Aditxt NASDAQ:ADTX

$1.20 +0.04 (+3.02%)

As of 11:08 AM Eastern

Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

GlycoMimetics NASDAQ:GLYC

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

GENPREX NASDAQ:GNPX

$0.25 -0.03 (-9.35%)

As of 11:08 AM Eastern

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

LakeShore Biopharma NASDAQ:LSB

$1.08 +0.04 (+4.32%)

As of 10:59 AM Eastern

LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time